Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBTMN5)

Drug Name

Sophoraflavanone G Drug Info

Synonyms

Sophoraflavanone G; Vexibinol; 97938-30-2; (2S)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-8-[(2R)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl]-2,3-dihydro-4H-chromen-4-one; norkurarinone; CHEMBL243148; CHEBI:50209; (2S)-5,7,2',4'-tetrahydroxy-8-lavandulylflavanone; Kushnol F; (2S)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-8-[(2R)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]-2,3-dihydrochromen-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(2,4-dihydroxyphenyl)-8-(5-methyl-2-(1-methylethenyl)-4-hexenyl)-, (S-(R*,S*))-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 72936
ChEBI ID: CHEBI:50209
CAS Number: CAS 97938-30-2
TTD Drug ID: DMBTMN5
VARIDT Drug ID: DR00953

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Sodium/glucose cotransporter 1 (SGLT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sotagliflozin	DMMLXA9	Heart failure	BD10-BD13	Approved	[2]
LIK-066	DM32NWD	Heart failure	BD10-BD13	Phase 2	[3]
YG1699	DM1NR1J	Type-1 diabetes	5A10	Phase 2	[4]
1614235 + 2330672	DMD751X	Type-2 diabetes	5A11	Phase 1	[3]
GSK1614235	DM7I1AQ	Type-2 diabetes	5A11	Phase 1	[5]
LX2761	DM8ZS7T	Type 2 diabetes	5A11	Phase 1	[6]
T-1095	DMGFS51	Diabetic complication	5A2Y	Discontinued in Phase 2	[7]
KURAIDIN	DMLDUJ1	Discovery agent	N.A.	Investigative	[1]
KURARINONE	DMH0G8W	Discovery agent	N.A.	Investigative	[1]
10-methoxy-N(1)-methylburnamine-17-O-veratrate	DMJW25X	Discovery agent	N.A.	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting SLC5A2 messenger RNA (SLC5A2 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bexagliflozin	DMK56G0	Type 2 diabetes	5A11	Approved	[9]
ISIS-SGLT2	DMDKAIC	Type-2 diabetes	5A11	Phase 1	[10]
KURAIDIN	DMLDUJ1	Discovery agent	N.A.	Investigative	[1]
KURARINONE	DMH0G8W	Discovery agent	N.A.	Investigative	[1]
10-methoxy-N(1)-methylburnamine-17-O-veratrate	DMJW25X	Discovery agent	N.A.	Investigative	[8]
Alstiphyllanine F	DMKRAEW	Discovery agent	N.A.	Investigative	[8]
Kushenol N	DMY13UR	Discovery agent	N.A.	Investigative	[1]
Alstiphyllanine E	DMTNQ5E	Discovery agent	N.A.	Investigative	[8]
Burnamine-17-O-3',4',5'-trimethoxybenzoate	DMBO0WI	Discovery agent	N.A.	Investigative	[8]
Alstiphyllanine D	DM2FLDJ	Discovery agent	N.A.	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
SLC5A2 messenger RNA (SLC5A2 mRNA)	TTF8JAT	SC5A2_HUMAN	Inhibitor	[1]
Sodium/glucose cotransporter 1 (SGLT1)	TT2UE56	SC5A1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9.
2	LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69.
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 915).
4	ClinicalTrials.gov (NCT04956263) A Comparison of Postprandial Glucose After a Mixed Meal Tolerance Test, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study of the Dual Systemic SGLT1 and SGLT2 Inhibitor YG1699, and the Selective SGLT2 Inhibitor Dapagliflozin in Subjects With Type 1 Diabetes. U.S.National Institutes of Health.
5	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
6	Clinical pipeline report, company report or official report of Lexicon Pharmaceuticals.
7	T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999 Sep;48(9):1794-800.
8	Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158.
9	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).